Article Sidebar

Published
Nov 17, 2025
Download
PDF
Statistic
Read Counter: 1 Download: 3

Main Article Content

Abstract

Diabetes mellitus is a most common endocrine disorder, affecting more than 300 million people worldwide. For these therapies developed along the principles of allopathic are often limited in efficacy, Carry the risk of adverse effects, and are often too costly, especially for the developing world. In order to identify complementary or alternative approaches to existing medications, we studied the anti-diabetic potential of leaves of A.Racemosus. The acute oral toxicity studies of the extracts revealed no toxic effects up to the levels of 2000mg/kg b.wt. The aqueous and alcoholic extracts of 20 and 30mg/kg body weight of A.Racemosus was screened for the presence of hypoglycemic and antidiabetic activity. In this study diabetes was induced by a single IP dose Alloxan monohydrate in 72hrs fasted rats. The FBGL was carried on 7th, 14th and 21st day and OGTT was measured on 8th, 15th and 22nd day. Glibeclamide was taken as the standard and the results are quite comparable with it. The studies were indicated that the leaves of A.Racemosus are effective in regeneration of insulin secreting β-cells and thus possess antidiabetic activity. The aqueous and alcoholic extracts showed significant effect in decreasing the Fasting blood Glucose level and oral glucose tolerance test of rats and it’s also showed good hypoglycemic activity in normal glycemic rats. The preliminary phytochemical analysis of the extracts of A.Racemosus revealed the presence of alkaloids, tannins, saponins, terpenoids, flavonoids, phenolics and glycoside as the possible biologically active principles.

Keywords

A.Racemosus , Alloxan monohydrate, Glibenclamide, FBGL and OGTT.

Article Details

References

  1. 1. Consultation, W. H. O. Definition, diagnosis and classification of diabetes mellitus and its complications. Vol. 1. Part, 1999.
  2. 2. Alberti, Kurt George Matthew Mayer, and PZ ft Zimmet. "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation." Diabetic medicine 15.7 (1998): 539-553.
  3. 3. Gress, Todd W., et al. "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus." New England Journal of Medicine 342.13 (2000): 905-912.
  4. 4. Ahmed, Awad M. "History of diabetes mellitus." Saudi medical journal 23.4 (2002): 373-378.
  5. 5. Zimmet, Paul Z., Daniel J. McCarty, and Maximilian P. de Courten. "The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome." Journal of Diabetes and its Complications 11.2 (1997): 60-68.
  6. 6. American Diabetes Association. "Type 2 diabetes in children and adolescents."Pediatrics 105.3 (2000): 671-680.
  7. 7. Saltiel, Alan R., and C. Ronald Kahn. "Insulin signalling and the regulation of glucose and lipid metabolism." Nature 414.6865 (2001): 799-806.
  8. 8. Browning, Jeffrey D., and Jay D. Horton. "Molecular mediators of hepatic steatosis and liver injury." Journal of Clinical Investigation 114.2 (2004): 147-152.
  9. 9. Aronoff, Stephen L., et al. "Glucose metabolism and regulation: beyond insulin and glucagon." Diabetes Spectrum 17.3 (2004): 183-190.
  10. 10. Ross, E. J., and D. C. Linch. "Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis." The Lancet320.8299 (1982): 646-649.
  11. 11. Levin, Marvin E., Vincenza C. Boisseau, and Louis V. Avioli. "Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes." New England Journal of Medicine 294.5 (1976): 241-245.
  12. 12. Sherwin, Robert, and Philip Felig. "Pathophysiology of diabetes mellitus." The Medical clinics of North America 62.4 (1978): 695-711.
  13. 13. Faber, O. K., and C. Binder. "C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus." Diabetes 26.7 (1977): 605-610.
  14. 14. Ioannidis, Ioannis. "Pathophysiology of Type 1 diabetes." Diabetes in Clinical Practice: Questions and Answers from Case Studies 31 (2007): 23.
  15. 15. Scheen, A. J. "Pathophysiology of type 2 diabetes." Acta Clinica Belgica 58.6 (2003): 335-341.
  16. 16. Vambergue, A., et al. "[Pathophysiology of gestational diabetes]." Journal de gynecologie, obstetrique et biologie de la reproduction 31.6 Suppl (2002): 4S3-4S10.
  17. 17. Inzucchi, Silvio E. "Diagnosis of diabetes." New England Journal of Medicine367.6 (2012): 542-550.
  18. 18. Turner, R. C., et al. "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)." lancet 352.9131 (1998): 837-853.
  19. 19. Brownlee, M., and A. Cerami. "The biochemistry of the complications of diabetes mellitus." Annual review of biochemistry 50.1 (1981): 385-432.
  20. 20. Pari, L., and G. Saravanan. "Antidiabetic effect of Cogent db, a herbal drug in alloxan-induced diabetes mellitus." Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology 131.1 (2002): 19-25.
  21. 21. Day, Caroline. "Traditional plant treatments for diabetes mellitus: pharmaceutical foods." British Journal of Nutrition 80.01 (1998): 5-6.
  22. 22. Smith, George Davey, et al. "Genetic epidemiology and public health: hope, hype, and future prospects." The Lancet 366.9495 (2005): 1484-1498.
  23. 23. Kamat, Jayashree P., et al. "Antioxidant properties of< i> Asparagus racemosus against damage induced by γ-radiation in rat liver mitochondria." Journal of ethnopharmacology 71.3 (2000): 425-435.
  24. 24. Goel, R. K., and K. Sairam. "Anti-ulcer drugs from indigenous sources with emphasis on Musa sapientum, tamrahbasma, Asparagus racemosus and Zingiber officinale." Indian journal of pharmacology 34.2 (2002): 100-110.
  25. 25. Sairam, K., et al. "Gastroduodenal ulcer protective activity of< i> Asparagus racemosus: an experimental, biochemical and histological study." Journal of ethnopharmacology 86.1 (2003): 1-10.
  26. 26. Mandal, Subhash C., et al. "Evaluation of antibacterial activity of Asparagus racemosus Willd. root." Phytotherapy Research 14.2 (2000): 118-119.
  27. 27. Venkatesan, N., et al. "Anti-diarrhoeal potential of Asparagus racemosus wild root extracts in laboratory animals." J Pharm Pharmaceut Sci 8.1 (2005): 39-46.
  28. 28. Wiboonpun, Nathathai, Preecha Phuwapraisirisan, and Santi Tip‐pyang. "Identification of antioxidant compound from Asparagus racemosus."Phytotherapy Research 18.9 (2004): 771-773.
  29. 29. Gautam, Manish, et al. "Immunoadjuvant potential of< i> Asparagus racemosus aqueous extract in experimental system." Journal of ethnopharmacology 91.2 (2004): 251-255.
  30. 30. Dalvi, S. S., P. M. Nadkarni, and K. C. Gupta. "Effect of Asparagus racemosus (Shatavari) on gastric emptying time in normal healthy volunteers." Journal of postgraduate medicine 36.2 (1990): 91.
  31. 31. Visavadiya, N. P. "Hypolipidemic and antioxidant activities of Asparagus racemosus in hypercholesteremic rats." Indian Journal of Pharmacology 37.6 (2005): 376.
  32. 32. Mandal, Subhash C., et al. "Antitussive effect of< i> Asparagus racemosus root against sulfur dioxide-induced cough in mice." Fitoterapia 71.6 (2000): 686-689.
  33. 33. Gautam, Manish, et al. "Immunomodulatory activity of< i> Asparagus racemosus on systemic Th1/Th2 immunity: Implications for immunoadjuvant potential." Journal of ethnopharmacology 121.2 (2009): 241-247.
  34. 34. Pandey, S. K., et al. "Effect of Asparagus racemosus rhizome (Shatavari) on mammary gland and genital organs of pregnant rat." Phytotherapy research19.8 (2005): 721-724.
  35. 35. Singh, Gireesh K., et al. "Antidepressant activity of< i> Asparagus racemosus in rodent models." Pharmacology Biochemistry and Behavior91.3 (2009): 283-290.
  36. 36. Hannan, J. M. A., et al. "Insulin secretory actions of extracts of Asparagus racemosus root in perfused pancreas, isolated islets and clonal pancreatic β-cells." Journal of endocrinology 192.1 (2007): 159-168.
  37. 37. Wani, Javeed Ahmed, Rajeshwara N. Achur, and R. K. Nema. "Phytochemical screening and aphrodisiac activity of Asparagus racemosus." studies 8 (2011): 9.
  38. 38. Bhutani, K. K., et al. "Apoptosis inducing activity of steroidal constituents from< i> Solanum xanthocarpum and< i> Asparagus racemosus."Phytomedicine 17.10 (2010): 789-793.
  39. 39. Vadivelan, Ramachandran, et al. "Hypoglycemic, antioxidant and hypolipidemic activity of Asparagus racemosus on streptozotocin-induced diabetic in rats."Advances in Applied Science Research 2.3 (2011): 179-185.
  40. 40. Bhatnagar, M., and S. S. Sisodia. "Antisecretory and antiulcer activity of Asparagus racemosus Willd. against indomethacin plus pyloric ligation-induced gastric ulcer in rats." Journal of herbal pharmacotherapy 6.1 (2006): 13-20.
  41. 41. Palanisamy, N., and S. Manian. "Protective effects of Asparagus racemosus on oxidative damage in isoniazid-induced hepatotoxic rats an in vivo study."Toxicology and industrial health 28.3 (2012): 238-244.
  42. 42. Visavadiya, Nishant P., and A. V. R. L. Narasimhacharya. "Asparagus root regulates cholesterol metabolism and improves antioxidant status in hypercholesteremic rats." Evidence-Based Complementary and Alternative Medicine 6.2 (2009): 219-226.
  43. 43. Dhingra, Dinesh, and Vaibhav Kumar. "Pharmacological evaluation for antidepressant–like activity of Asparagus racemosus wild in mice."Pharmacologyonline 3 (2007): 133-152.
  44. 44. Hannan, J. M. A., et al. "Antihyperglycaemic activity of Asparagus racemosus roots is partly mediated by inhibition of carbohydrate digestion and absorption, and enhancement of cellular insulin action." British Journal of Nutrition 107.09 (2012): 1316-1323.
  45. 45. El-Demerdash, F. M., M. I. Yousef, and N. I. El-Naga. "Biochemical study on the hypoglycemic effects of onion and garlic in alloxan-induced diabetic rats."Food and Chemical Toxicology 43.1 (2005): 57-63.
  46. 46. Stanely, P., Mainzen Prince, and Venugopal P. Menon. "Hypoglycaemic and other related actions of< i> Tinospora cordifolia roots in alloxan-induced diabetic rats." Journal of ethnopharmacology 70.1 (2000): 9-15.
  47. 47. Pari, L., and J. Uma Maheswari. "Hypoglycaemic effect of< i> Musa sapientum L. in alloxan-induced diabetic rats." Journal of ethnopharmacology 68.1 (1999): 321-325.
  48. 48. Sharma, S. B., et al. "Hypoglycaemic and hypolipidemic effect of ethanolic extract of seeds of< i> Eugenia jambolana in alloxan-induced diabetic rabbits." Journal of Ethnopharmacology 85.2 (2003): 201-206.
  49. 49. Kameswara Rao, B., et al. "Antidiabetic activity of< i> Terminalia< i> pallida fruit in alloxan induced diabetic rats." Journal of Ethnopharmacology85.1 (2003): 169-172.
  50. 50. Sachdewa, Archana, and L. D. Khemani. "Effect of< i> Hibiscus rosa sinensis Linn. ethanol flower extract on blood glucose and lipid profile in streptozotocin induced diabetes in rats." Journal of Ethnopharmacology 89.1 (2003): 61-66.
  51. 51. Hwang, Hye-Jin, et al. "Hypoglycemic effect of crude exopolysaccharides produced by a medicinal mushroom< i> Phellinus baumii in streptozotocin-induced diabetic rats." Life sciences 76.26 (2005): 3069-3080.
  52. 52. Singh, Som Nath, et al. "Effect of an antidiabetic extract of< i> Catharanthus roseus on enzymic activities in streptozotocin induced diabetic rats."Journal of Ethnopharmacology 76.3 (2001): 269-277.
  53. 53. Ahmed, I., et al. "Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic< i> Momordica charantia(karela) fruit extract in streptozotocin-induced diabetic rats." Diabetes Research and Clinical Practice 51.3 (2001): 155-161.
  54. 54. Eidi, A., M. Eidi, and E. Esmaeili. "Antidiabetic effect of garlic (< i> Allium sativum L.) in normal and streptozotocin-induced diabetic rats."Phytomedicine 13.9 (2006): 624-629.